FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy
Related Topics >> Glaxosmithkline | Sustainability

Corporate green goals driving PAT adoption

Free Newsletter

FiercePharma Manufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Sign up today to receive your FREE "insiders only" weekly pharma manufacturing industry briefing.



Tools

GlaxoSmithKline plant managers are jumping on the process analytical technology train. But process control is not the sole driver. GSK, like other drugmakers, is seeing PAT provide a boost for its sustainability efforts.

The trend is currently most apparent in its pilot plants, according to PharmaManufacturing.com. Managers trying to reduce cycle times and realize energy and cost savings are considering and adopting the technology.

In a recent survey conducted by the online magazine, ten percent of respondents say that sustainability has become a key driver of their PAT efforts. About half of the 50 respondents say they see PAT as a means toward sustainability and green practices.

PAT has "moved up in status, and moved upstream in the development cycle," according to the article. "Manufacturers are beginning to equate PAT with reducing the environmental impact of processes."

- here's the article

Related Articles:
Millipore boasts progress on green initiatives
Plant design emphasizes green
Pharma finds means to go green


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:

More stories about Glaxosmithkline   Sustainability